Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | HPGD | P15428 | 7/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31475465 | 1.00 | LMNA (0.67) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2795205 | 0.83 | KDM4E (0.67) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8210948 | 0.82 | LMNA (0.56) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2272868 | 0.82 | ALDH1A1 (0.59) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8214267 | 0.82 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23696299 | 0.82 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5453934 | 0.82 | ALDH1A1 (0.53) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31081977 | 0.82 | ALDH1A1 (0.59) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1224662 | 0.80 | LMNA (0.62) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3151814 | 0.80 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196455-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| WO-2018138362-A1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXA ZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| EP-3318557-A2 | QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-05-09 | — | — | EP | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
| US-5112837-A | Inhibitors of thymidylate synthetase enzyme | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-12 | — | — | US | disclosed |
| EP-0318225-A2 | 6-Aryl aminomethyl quinoline derivatives and their use as anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | LMNA 4749/4885KDM4E 1553/4885ALDH1A1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.